Last edition
News about "ProtheraCytes Japan"
CellProthera and Alfresa Sign MOU to Advance ProtheraCytes Phase 3 in Japan
CellProthera and Alfresa Holdings have signed a Memorandum of Understanding (MOU) to advance ProtheraCytes phase 3 development and future wholesale distribution in Japan for severe myocardial infarction.
ProtheraCytes Japan | 13/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members